These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 17218325)

  • 1. Modelling the impact on Hepatitis C transmission of reducing syringe sharing: London case study.
    Vickerman P; Hickman M; Judd A
    Int J Epidemiol; 2007 Apr; 36(2):396-405. PubMed ID: 17218325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Injecting behaviours and prevalence of hepatitis B, C and D markers in New Zealand injecting drug user populations.
    Kemp R; Miller J; Lungley S; Baker M
    N Z Med J; 1998 Feb; 111(1060):50-3. PubMed ID: 9539916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Harm reduction interventions, behaviours and associated health outcomes in France, 1996-2003.
    Emmanuelli J; Desenclos JC
    Addiction; 2005 Nov; 100(11):1690-700. PubMed ID: 16277629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis C virus infection, HIV co-infection, and associated risk among injecting drug users in Togliatti, Russia.
    Rhodes T; Platt L; Judd A; Mikhailova LA; Sarang A; Wallis N; Alpatova T; Hickman M; Parry JV
    Int J STD AIDS; 2005 Nov; 16(11):749-54. PubMed ID: 16303071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High HIV and hepatitis C prevalence amongst injecting drug users in Mauritius: findings from a population size estimation and respondent driven sampling survey.
    Johnston L; Saumtally A; Corceal S; Mahadoo I; Oodally F
    Int J Drug Policy; 2011 Jul; 22(4):252-8. PubMed ID: 21700442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk behaviors and antibody hepatitis B and C prevalence among injecting drug users in south-western Sydney, Australia.
    Maher L; Chant K; Jalaludin B; Sargent P
    J Gastroenterol Hepatol; 2004 Oct; 19(10):1114-20. PubMed ID: 15377287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales.
    Sutton AJ; Gay NJ; Edmunds WJ; Hope VD; Gill ON; Hickman M
    BMC Infect Dis; 2006 Jun; 6():93. PubMed ID: 16762050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of, and risk factors for, hepatitis C virus infection among recent initiates to injecting in London and Glasgow: cross sectional analysis.
    Judd A; Hutchinson S; Wadd S; Hickman M; Taylor A; Jones S; Parry JV; Cameron S; Rhodes T; Ahmed S; Bird S; Fox R; Renton A; Stimson GV; Goldberg D
    J Viral Hepat; 2005 Nov; 12(6):655-62. PubMed ID: 16255768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrating multiple programme and policy approaches to hepatitis C prevention and care for injection drug users: a comprehensive approach.
    Birkhead GS; Klein SJ; Candelas AR; O'Connell DA; Rothman JR; Feldman IS; Tsui DS; Cotroneo RA; Flanigan CA
    Int J Drug Policy; 2007 Oct; 18(5):417-25. PubMed ID: 17854731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating population attributable risk for hepatitis C seroconversion in injecting drug users in Australia: implications for prevention policy and planning.
    Wand H; Spiegelman D; Law M; Jalaludin B; Kaldor J; Maher L
    Addiction; 2009 Dec; 104(12):2049-56. PubMed ID: 19804463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in the injecting risk behaviour of injecting drug users in London, 1990-1993.
    Hunter GM; Donoghoe MC; Stimson GV; Rhodes T; Chalmers CP
    AIDS; 1995 May; 9(5):493-501. PubMed ID: 7639975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A syringe exchange programme in prison as prevention strategy against HIV infection and hepatitis B and C in Berlin, Germany.
    Stark K; Herrmann U; Ehrhardt S; Bienzle U
    Epidemiol Infect; 2006 Aug; 134(4):814-9. PubMed ID: 16371183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews.
    Palmateer N; Kimber J; Hickman M; Hutchinson S; Rhodes T; Goldberg D
    Addiction; 2010 May; 105(5):844-59. PubMed ID: 20219055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia.
    Maher L; Jalaludin B; Chant KG; Jayasuriya R; Sladden T; Kaldor JM; Sargent PL
    Addiction; 2006 Oct; 101(10):1499-508. PubMed ID: 16968352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modelling the transmission of HIV and HCV among injecting drug users in Rawalpindi, a low HCV prevalence setting in Pakistan.
    Vickerman P; Platt L; Hawkes S
    Sex Transm Infect; 2009 Apr; 85 Suppl 2():ii23-30. PubMed ID: 19307347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C and its risk management among drug injectors in London: renewing harm reduction in the context of uncertainty.
    Rhodes T; Davis M; Judd A
    Addiction; 2004 May; 99(5):621-33. PubMed ID: 15078237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evaluation of a pilot study on needle and syringe exchange program among injecting drug users in a community in Guangdong, China].
    Lin P; Fan ZF; Yang F; Wu ZY; Wang Y; Liu YY; Ming ZQ; Li WJ; Luo W; Fu XB; Mai XR; Xu RH; Feng WY; He Q
    Zhonghua Yu Fang Yi Xue Za Zhi; 2004 Sep; 38(5):305-8. PubMed ID: 15498241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence rates and risk factors for hepatitis C among drug users not in treatment in Malaysia.
    Vicknasingam B; Narayanan S; Navaratnam V
    Drug Alcohol Rev; 2009 Jul; 28(4):447-54. PubMed ID: 19594801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modelling the prevalence of HCV amongst people who inject drugs: an investigation into the risks associated with injecting paraphernalia sharing.
    Corson S; Greenhalgh D; Taylor A; Palmateer N; Goldberg D; Hutchinson S
    Drug Alcohol Depend; 2013 Nov; 133(1):172-9. PubMed ID: 23791029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C prevalence and needle/syringe sharing behaviours in recent onset injecting drug users.
    Robinson GM; Reynolds JN; Robinson BJ
    N Z Med J; 1995 Mar; 108(996):103-5. PubMed ID: 7715873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.